Prevention of early readmission after acute decompensated heart failure

Acute heart failure (AHF) is a global pandemic with more than one million admissions to hospital annually in the USA and millions more worldwide [1,2]. Post-discharge event rates remain exceptionally high. Although global clinical trials and national hospitalized HF registries have not led to the development of new therapies to improve mortality and readmissions in patients with AHF, they have significantly improved our understanding of patients with this complex syndrome [1].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research